newsfilter
← Latest News
GlobeNewswire·

BioAtla Reports First Quarter 2025 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study ongoing, dosed first three patients at 300 micrograms; data readout expected mid-2025 with dose expansion data readout anticipated 1H 2026Mecbotamab vedotin